Skip to content

Study · Case report or series · n = 1 · 1989

4 results

Immunoglobulin-mediated hypersensitivity in response to long-term treatment with gonadorelin hydrochloride (Factrel) in a female patient.

Foster WG, Jarrell JF, Dolovich J, YoungLai EV

American journal of obstetrics and gynecology1 Apr 1989Cited by 4 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a patient with severe hypogonadotropic hypogonadism, LHRH (Factrel) given by infusion pump was followed by a wheal-and-flare reaction at the injection sites.

    In plain wordsA woman with severe hypogonadotropic hypogonadism developed a skin reaction at the sites where LHRH was injected by pump.

    Outcome
    IncreaseInjection-site reaction to long-term LHRH
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection.
  2. 02HumanCase report or seriesSafety outcome

    In this patient, the skin prick test was positive for LHRH and negative for the vehicle.

    In plain wordsIn this patient, a skin prick test reacted to LHRH but not to the vehicle.

    Outcome
    IncreaseSkin prick test to LHRH
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Skin testing by skin prick test was positive for luteinizing hormone-releasing hormone but negative for vehicle.
    1 context sentence
    Summary · context
    Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection.
  3. 03HumanCase report or seriesSafety outcome

    In this patient, radioallergosorbent testing was negative for LHRH-reactive IgE antibodies.

    In plain wordsIn this patient, a radioallergosorbent test found no LHRH-reactive IgE antibodies.

    Outcome
    No significant changeLHRH-reactive IgE by radioallergosorbent testing
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Radioallergosorbent testing was negative for luteinizing hormone-releasing hormone-reactive immunoglobulin E antibodies.
    1 context sentence
    Summary · context
    Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection.
  4. 04HumanCase report or seriesSafety outcome

    In this patient, radioimmunoassay of serum was positive for antibody to LHRH, only for immunoglobulin E.

    In plain wordsIn this patient, a blood test found antibody to LHRH, only of the IgE type.

    Outcome
    IncreaseAnti-LHRH antibody by radioimmunoassay
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Radioimmunoassay of serum of the allergic patient antibody to luteinizing hormone-releasing hormone was positive only for immunoglobulin E.
    1 context sentence
    Summary · context
    Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.